2016
Toward Repurposing Metformin as a Precision Anti-Cancer Therapy Using Structural Systems Pharmacology
Hart T, Dider S, Han W, Xu H, Zhao Z, Xie L. Toward Repurposing Metformin as a Precision Anti-Cancer Therapy Using Structural Systems Pharmacology. Scientific Reports 2016, 6: 20441. PMID: 26841718, PMCID: PMC4740793, DOI: 10.1038/srep20441.Peer-Reviewed Original ResearchConceptsPrecision anti-cancer therapyMolecular basisAnti-cancer therapyStructural systems pharmacologyProtein-protein interactionsDrug target identificationNetwork biology analysisMolecular targetsInteractomic dataGenetic interactionsStructural proteomeGenetic networksKey molecular targetsPhenotypic responsesKinase targetsBiology analysisCancer mutationsPleiotropic effectsAnti-cancer effectsNetwork biomarkersTarget identificationGenetic biomarkersSystems pharmacology approachKey nodesTarget
2015
Oncogenes and tumor suppressor genes: comparative genomics and network perspectives
Zhu K, Liu Q, Zhou Y, Tao C, Zhao Z, Sun J, Xu H. Oncogenes and tumor suppressor genes: comparative genomics and network perspectives. BMC Genomics 2015, 16: s8. PMID: 26099335, PMCID: PMC4474543, DOI: 10.1186/1471-2164-16-s7-s8.Peer-Reviewed Original ResearchConceptsTumor suppressor geneEssential genesTSG proteinsEssential proteinsHuman protein-protein interaction networkCancer drug target proteinsSuppressor geneWhole human interactomeProtein-protein interaction networkCancer developmentMutation frequencyDirect interactionDrug target identificationCancer drug targetSomatic mutationsDrug target proteinsDrug target genesComparative genomicsLow mutation frequencyCellular functionsHuman interactomeMutation patternsGenetic variationGene setsHigh mutation frequency